Azin Behnood-Rod1, Ranjithkumar Chellian1, Ryann Wilson1, Takato Hiranita2, Abhisheak Sharma3, Francisco Leon4, Christopher R McCurdy5, Lance R McMahon2, Adriaan W Bruijnzeel6. 1. Department of Psychiatry, University of Florida, Gainesville, FL, USA. 2. Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA. 3. Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, USA; Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA. 4. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. 5. Translational Drug Development Core, Clinical and Translational Sciences Institute, University of Florida, Gainesville, FL, USA; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. 6. Department of Psychiatry, University of Florida, Gainesville, FL, USA. Electronic address: awbruijn@ufl.edu.
Abstract
BACKGROUND: Kratom (Mitragyna speciosa Korth.) has been used in Southeast Asia for hundreds of years to increase energy, for relaxation, and to diminish opioid withdrawal. Kratom use has recently spread to Western countries. Kratom could potentially be used for the treatment of opioid withdrawal and pain, but more insight is needed into its abuse potential. Therefore, we investigated the rewarding properties of the primary kratom alkaloid mitragynine and its active metabolite 7-hydroxymitragynine, and morphine as a reference drug in male and female rats. These compounds have agonist activity at mu-opioid receptors. METHODS: The compounds were tested in an intracranial self-stimulation (ICSS) procedure, which allows for the evaluation of the rewarding/aversive and sedative effects of drugs. Rewarding doses of drugs decrease the brain reward thresholds, and aversive drug doses have the opposite effect. RESULTS: Mitragynine, 7-hydroxymitragynine, and morphine affected the brain reward thresholds. A high dose of 7-hydroxymitragynine (3.2 mg/kg) increased the brain reward thresholds, whereas an intermediate dose of morphine (10 mg/kg) decreased the reward thresholds. 7-Hydroxymitragynine and morphine affected the response latencies. Five mg/kg of morphine increased response latencies. 7-Hydroxymitragynine tended to increase the response latencies, but the post hoc analyses did not reveal a significant effect. There were no sex differences in the effects of mitragynine, 7-hydroxymitragynine, and morphine on the reward thresholds and the response latencies. CONCLUSIONS: These initial findings indicate that mitragynine and 7-hydroxymitragynine are not rewarding in the ICSS procedure. The present results suggest that these kratom alkaloids do not have abuse potential.
BACKGROUND:Kratom (Mitragyna speciosa Korth.) has been used in Southeast Asia for hundreds of years to increase energy, for relaxation, and to diminish opioid withdrawal. Kratom use has recently spread to Western countries. Kratom could potentially be used for the treatment of opioid withdrawal and pain, but more insight is needed into its abuse potential. Therefore, we investigated the rewarding properties of the primary kratom alkaloid mitragynine and its active metabolite 7-hydroxymitragynine, and morphine as a reference drug in male and female rats. These compounds have agonist activity at mu-opioid receptors. METHODS: The compounds were tested in an intracranial self-stimulation (ICSS) procedure, which allows for the evaluation of the rewarding/aversive and sedative effects of drugs. Rewarding doses of drugs decrease the brain reward thresholds, and aversive drug doses have the opposite effect. RESULTS:Mitragynine, 7-hydroxymitragynine, and morphine affected the brain reward thresholds. A high dose of 7-hydroxymitragynine (3.2 mg/kg) increased the brain reward thresholds, whereas an intermediate dose of morphine (10 mg/kg) decreased the reward thresholds. 7-Hydroxymitragynine and morphine affected the response latencies. Five mg/kg of morphine increased response latencies. 7-Hydroxymitragynine tended to increase the response latencies, but the post hoc analyses did not reveal a significant effect. There were no sex differences in the effects of mitragynine, 7-hydroxymitragynine, and morphine on the reward thresholds and the response latencies. CONCLUSIONS: These initial findings indicate that mitragynine and 7-hydroxymitragynine are not rewarding in the ICSS procedure. The present results suggest that these kratomalkaloids do not have abuse potential.
Authors: Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames Journal: J Am Chem Soc Date: 2016-05-18 Impact factor: 15.419
Authors: Samuel Obeng; Shyam H Kamble; Morgan E Reeves; Luis F Restrepo; Avi Patel; Mira Behnke; Nelson J-Y Chear; Surash Ramanathan; Abhisheak Sharma; Francisco León; Takato Hiranita; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy Journal: J Med Chem Date: 2019-12-27 Impact factor: 7.446
Authors: Erin C Berthold; Shyam H Kamble; Kanumuri S Raju; Michelle A Kuntz; Alexandria S Senetra; Marco Mottinelli; Francisco León; Luis F Restrepo; Avi Patel; Nicholas P Ho; Takato Hiranita; Abhisheak Sharma; Lance R McMahon; Christopher R McCurdy Journal: Drug Metab Dispos Date: 2021-11-10 Impact factor: 3.922
Authors: Marc T Swogger; Kirsten E Smith; Albert Garcia-Romeu; Oliver Grundmann; Charles A Veltri; Jack E Henningfield; Lorna Y Busch Journal: Front Pharmacol Date: 2022-03-02 Impact factor: 5.810
Authors: Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers Journal: Hum Psychopharmacol Date: 2021-07-26 Impact factor: 2.130